BioCentury
ARTICLE | Company News

Halaven sales and marketing update

November 7, 2016 11:14 PM UTC

The U.K.’s NICE issued a final appraisal determination (FAD) recommending the use of Halaven eribulin mesylate to treat advanced or metastatic breast cancer in patients who have received ≥2 prior chem...

BCIQ Company Profiles

Eisai Co. Ltd.